Charles River Laboratories International (CRL) vs Revvity (RVTY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Charles River Laboratories International (CRL) has outperformed Revvity (RVTY) over the past year, gaining 71.8% versus a gain of 65.8%. Over five years, RVTY leads with a -10.4% price change compared with -26.2% for CRL. Revvity is the larger company by market cap ($17.22 billion vs $14.52 billion), about 1.2 times the size.
On valuation, Charles River Laboratories International trades at a lower forward P/E (23.6x vs 26.2x for Revvity). Revvity pays a dividend yielding 0.18%, while Charles River Laboratories International does not currently pay one. Revvity converts more of its revenue into profit, with a net margin of 8.4% versus -3.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRL | RVTY |
|---|---|---|
| Share price | $301.53 | $154.36 |
| Market cap | $14.52B | $17.22B |
| 1-day change | +1.18% | +1.45% |
| YTD return | +49.39% | +57.27% |
| 1-year return | +71.79% | +65.81% |
| 5-year return | -26.15% | -10.40% |
| P/E ratio (TTM) | — | 73.86 |
| Forward P/E | 23.60 | 26.21 |
| EPS (TTM) | $-4.80 | $2.09 |
| Dividend yield | 0.00% | 0.18% |
| Annual dividend | $0.00 | $0.28 |
| Revenue (latest FY) | $4.02B | $2.86B |
| Revenue growth (YoY) | -0.85% | +3.67% |
| Net income (latest FY) | $-144.34M | $241.20M |
| Operating margin | 0.63% | 12.49% |
| Net margin | -3.59% | 8.45% |
| 52-week high | $333.30 | $166.25 |
| 52-week low | $146.20 | $81.22 |
| Distance from 52-week high | -9.53% | -7.15% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +1.15% | -11.98% |
| Average volume | 956.13K | 1.79M |
| Shares outstanding | 48.17M | 111.59M |
| Employees | 18,300 | 11,000 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Revvity is more profitable, keeping 8.4 cents of every revenue dollar as net income versus -3.6 cents for Charles River Laboratories International.
- The two companies sit in different sectors: Charles River Laboratories International in Health Care and Revvity in Industrials.
About Charles River Laboratories International
CRL stock →Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 18,300 employees
About Revvity
RVTY stock →Revvity, Inc. provides health sciences solutions, technologies, and services.
Industrials · Biotechnology: Laboratory Analytical Instruments · 11,000 employees
CRL vs RVTY FAQ
Which is bigger, Charles River Laboratories International or Revvity?
Revvity (RVTY) is larger, with a market capitalization of $17.22B compared with $14.52B for Charles River Laboratories International (CRL).
Which stock has performed better over the past year, CRL or RVTY?
CRL returned +71.79% over the past 12 months, compared with +65.81% for RVTY (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Charles River Laboratories International or Revvity?
Revvity pays a dividend yielding 0.18%, while Charles River Laboratories International does not currently pay a regular dividend.
Are Charles River Laboratories International and Revvity in the same industry?
No. Charles River Laboratories International is in the Health Care sector, while Revvity is in Industrials.